Dr. Graff on the Safety of Checkpoint Inhibition in mCRPC

Mar 18, 2020

Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the safety profile of pembrolizumab (Keytruda) plus enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Now that checkpoint inhibitors are approved for use in several disease states, the risks with these agents are becoming more well-known, explains Graff. The combination of enzalutamide and pembrolizumab, or any PD-1 inhibitor, appears to result in more rashes for patients with mCRPC, says Graff.

Results of the KETNOTE-199 trial, in which patients with mCRPC received pembrolizumab plus enzalutamide, showed that 25% of patients developed a rash. Of those cases, only 1 was grade 3 and required intravenous steroids. The rest of the patients were managed with topical or oral steroids. Otherwise, the safety profile of pembrolizumab plus enzalutamide was as expected, concludes Graff.

Related Videos
View All
Related Content